Lori A Hazlehurst

Summary

Affiliation: H. Lee Moffitt Cancer Center and Research Institute
Country: USA

Publications

  1. ncbi request reprint Signaling networks associated with BCR-ABL-dependent transformation
    Lori A Hazlehurst
    Molecular Oncology Program, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA
    Cancer Control 16:100-7. 2009
  2. pmc Role of STAT3 in Transformation and Drug Resistance in CML
    Rajesh R Nair
    Molecular Oncology Program, H Lee Moffitt Cancer Center Tampa, FL, USA
    Front Oncol 2:30. 2012
  3. pmc MTI-101 (cyclized HYD1) binds a CD44 containing complex and induces necrotic cell death in multiple myeloma
    Anthony W Gebhard
    Corresponding Author Lori A Hazlehurst, Molecular Oncology Program, H Lee Moffitt Cancer Center, Tampa, FL
    Mol Cancer Ther 12:2446-58. 2013
  4. ncbi request reprint Cell adhesion to fibronectin (CAM-DR) influences acquired mitoxantrone resistance in U937 cells
    Lori A Hazlehurst
    Department of Interdisciplinary Oncology and Experimental Therapeutics Program, H Lee Moffitt Cancer Center and Research Institute at the University of South Florida, Tampa, Florida 33613, USA
    Cancer Res 66:2338-45. 2006
  5. pmc HYD1-induced increase in reactive oxygen species leads to autophagy and necrotic cell death in multiple myeloma cells
    Rajesh R Nair
    Moffitt Cancer Center, Tampa, Florida 33613, USA
    Mol Cancer Ther 8:2441-51. 2009
  6. pmc Beta1 integrin adhesion enhances IL-6-mediated STAT3 signaling in myeloma cells: implications for microenvironment influence on tumor survival and proliferation
    Kenneth H Shain
    Experimental Therapeutics and Oncologic Sciences Program, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA
    Cancer Res 69:1009-15. 2009
  7. pmc Stat3 contributes to resistance toward BCR-ABL inhibitors in a bone marrow microenvironment model of drug resistance
    Nadine N Bewry
    Molecular Oncology Program, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33613, USA
    Mol Cancer Ther 7:3169-75. 2008
  8. doi request reprint Targeting the Fanconi anemia/BRCA pathway circumvents drug resistance in multiple myeloma
    Danielle N Yarde
    Cancer Biology Ph D Program, University of South Florida, Tampa, Florida 33612, USA
    Cancer Res 69:9367-75. 2009
  9. pmc Potentiation of Nilotinib-mediated cell death in the context of the bone marrow microenvironment requires a promiscuous JAK inhibitor in CML
    Rajesh R Nair
    Molecular Oncology Program, H Lee Moffitt Cancer Center, Tampa, FL, USA
    Leuk Res 36:756-63. 2012
  10. pmc Acquisition of resistance toward HYD1 correlates with a reduction in cleaved α4 integrin expression and a compromised CAM-DR phenotype
    Michael F Emmons
    Molecular Oncology Program, H Lee Moffitt Cancer Center Tampa, FL, USA
    Mol Cancer Ther 10:2257-66. 2011

Research Grants

Collaborators

Detail Information

Publications23

  1. ncbi request reprint Signaling networks associated with BCR-ABL-dependent transformation
    Lori A Hazlehurst
    Molecular Oncology Program, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA
    Cancer Control 16:100-7. 2009
    ..The fusion protein BCR-ABL results in constitutive tyrosine kinase activity. It also affects downstream targets as well as the subcellular location of the normally tightly regulated Abl tyrosine kinase...
  2. pmc Role of STAT3 in Transformation and Drug Resistance in CML
    Rajesh R Nair
    Molecular Oncology Program, H Lee Moffitt Cancer Center Tampa, FL, USA
    Front Oncol 2:30. 2012
    ....
  3. pmc MTI-101 (cyclized HYD1) binds a CD44 containing complex and induces necrotic cell death in multiple myeloma
    Anthony W Gebhard
    Corresponding Author Lori A Hazlehurst, Molecular Oncology Program, H Lee Moffitt Cancer Center, Tampa, FL
    Mol Cancer Ther 12:2446-58. 2013
    ..Finally, we show that MTI-101 has robust activity as a single agent in the SCID-Hu bone implant and 5TGM1 in vivo model of multiple myeloma...
  4. ncbi request reprint Cell adhesion to fibronectin (CAM-DR) influences acquired mitoxantrone resistance in U937 cells
    Lori A Hazlehurst
    Department of Interdisciplinary Oncology and Experimental Therapeutics Program, H Lee Moffitt Cancer Center and Research Institute at the University of South Florida, Tampa, Florida 33613, USA
    Cancer Res 66:2338-45. 2006
    ..Taken together, our results suggest that the development of drug resistance models must consider interactions with the microenvironment to identify clinically relevant targets and mechanisms associated with acquired drug resistance...
  5. pmc HYD1-induced increase in reactive oxygen species leads to autophagy and necrotic cell death in multiple myeloma cells
    Rajesh R Nair
    Moffitt Cancer Center, Tampa, Florida 33613, USA
    Mol Cancer Ther 8:2441-51. 2009
    ..Taken together, our data describe an important role of ROS in HYD1-induced necrotic cell death in MM cells...
  6. pmc Beta1 integrin adhesion enhances IL-6-mediated STAT3 signaling in myeloma cells: implications for microenvironment influence on tumor survival and proliferation
    Kenneth H Shain
    Experimental Therapeutics and Oncologic Sciences Program, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA
    Cancer Res 69:1009-15. 2009
    ..Taken together, these results suggest a mechanism by which collaborative signaling by beta1 integrin and gp130 confers an increased survival advantage to MM cells...
  7. pmc Stat3 contributes to resistance toward BCR-ABL inhibitors in a bone marrow microenvironment model of drug resistance
    Nadine N Bewry
    Molecular Oncology Program, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33613, USA
    Mol Cancer Ther 7:3169-75. 2008
    ....
  8. doi request reprint Targeting the Fanconi anemia/BRCA pathway circumvents drug resistance in multiple myeloma
    Danielle N Yarde
    Cancer Biology Ph D Program, University of South Florida, Tampa, Florida 33612, USA
    Cancer Res 69:9367-75. 2009
    ....
  9. pmc Potentiation of Nilotinib-mediated cell death in the context of the bone marrow microenvironment requires a promiscuous JAK inhibitor in CML
    Rajesh R Nair
    Molecular Oncology Program, H Lee Moffitt Cancer Center, Tampa, FL, USA
    Leuk Res 36:756-63. 2012
    ..Finally, we demonstrate that in patient-derived primitive leukemic cells, co-cultured with BM stromal cells, inhibition of BCR-ABL and JAK activity was a successful strategy to potentiate their elimination...
  10. pmc Acquisition of resistance toward HYD1 correlates with a reduction in cleaved α4 integrin expression and a compromised CAM-DR phenotype
    Michael F Emmons
    Molecular Oncology Program, H Lee Moffitt Cancer Center Tampa, FL, USA
    Mol Cancer Ther 10:2257-66. 2011
    ..Moreover, our data provide further rationale for continued preclinical development of HYD1 and analogues of HYD1 for the treatment of multiple myeloma and potentially other tumors that home and/or metastasize to the bone...
  11. pmc Human multiple myeloma cells are sensitized to topoisomerase II inhibitors by CRM1 inhibition
    Joel G Turner
    Experimental Therapeutics Program and Department of Blood and Marrow Transplantation, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA
    Cancer Res 69:6899-905. 2009
    ..These results suggest that blocking topo IIalpha nuclear export sensitizes myeloma cells to topo II inhibitors. This method of sensitizing myeloma cells suggests a new therapeutic approach to multiple myeloma...
  12. pmc The FA/BRCA pathway is involved in melphalan-induced DNA interstrand cross-link repair and accounts for melphalan resistance in multiple myeloma cells
    Qing Chen
    Department of Interdisciplinary Oncology and Experimental Therapeutics Program, Biostatistics Core Facility, H Lee Moffitt Cancer Center and Research Institute at University of South Florida, 12902 Magnolia Dr, Tampa, FL 33612, USA
    Blood 106:698-705. 2005
    ..These data show that enhanced DNA repair via the Fanconi anemia/BRCA pathway is involved in acquired melphalan resistance. Our findings provide for a new target to enhance response to DNA cross-linking agents in cancer treatment...
  13. ncbi request reprint Emerging strategies for targeting cell adhesion in multiple myeloma
    Rajesh R Nair
    Molecular Oncology Program, H Lee Moffitt Cancer Center, Tampa, FL, USA
    Adv Pharmacol 65:143-89. 2012
    ..Ultimately, the goal is to use these therapies in combination with the existing antimyeloma agents in order to further reduce or abolish minimal residual disease and improve patient outcomes...
  14. pmc Development of highly potent and selective diaminothiazole inhibitors of cyclin-dependent kinases
    Ernst Schonbrunn
    Drug Discovery Department, H Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, Florida 33612, USA
    J Med Chem 56:3768-82. 2013
    ..Combined, the results demonstrate the potential of this new inhibitors series for further development into CDK-specific chemical probes or therapeutics...
  15. pmc Proteomic contributions to personalized cancer care
    John M Koomen
    H Lee Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, Florida 33612, USA
    Mol Cell Proteomics 7:1780-94. 2008
    ....
  16. pmc Tipifarnib-induced apoptosis in acute myeloid leukemia and multiple myeloma cells depends on Ca2+ influx through plasma membrane Ca2+ channels
    Niranjan Yanamandra
    Department of Interdisciplinary Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA
    J Pharmacol Exp Ther 337:636-43. 2011
    ..Our results indicate tipifarnib causes cell death via a novel mechanism involving activation of a plasma membrane Ca(2+) channel and intracellular Ca(2+) overload...
  17. doi request reprint Detection of DNA damage induced by topoisomerase II inhibitors, gamma radiation and crosslinking agents using the comet assay
    Lori A Hazlehurst
    Department of Interdisciplinary Oncology, Experimental Therapeutics and Drug Discovery Programs, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
    Methods Mol Biol 523:169-76. 2009
    ..In this chapter we will outline the comet assay for the detection of DNA damage induced by topoisomerase II inhibitors, cross-linking agents and gamma radiation...
  18. doi request reprint The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance
    Mark B Meads
    Department of Experimental Therapeutics, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA
    Clin Cancer Res 14:2519-26. 2008
    ..This protection allows tumor cells to survive the insult of chemotherapy, leading to minimal residual disease, and thereby increases the probability for the development of acquired drug resistance...
  19. pmc Cell adhesion induces p27Kip1-associated cell-cycle arrest through down-regulation of the SCFSkp2 ubiquitin ligase pathway in mantle-cell and other non-Hodgkin B-cell lymphomas
    Tint Lwin
    Department of Interdisciplinary Oncology and Experimental Therapeutics Program, H Lee Moffitt Cancer Center and Research Institute at the University of South Florida, Tampa, FL 33613, USA
    Blood 110:1631-8. 2007
    ..The understanding of this novel molecular pathway may prove valuable in designing new therapeutic approaches for modifying tumor cell growth and response to therapy...
  20. pmc The bone marrow microenvironment as a sanctuary for minimal residual disease in CML
    Rajesh R Nair
    Molecular Oncology Program, H Lee Moffitt Cancer Center, Tampa, FL 33612, United States
    Biochem Pharmacol 80:602-12. 2010
    ....
  21. ncbi request reprint Genotypic and phenotypic comparisons of de novo and acquired melphalan resistance in an isogenic multiple myeloma cell line model
    Lori A Hazlehurst
    Department of Interdisciplinary Oncology, H Lee Moffitt Cancer Center and Research Institute, at the University of South Florida, 12902 Magnolia Drive, Tampa, FL 33612, USA
    Cancer Res 63:7900-6. 2003
    ....
  22. doi request reprint The one-two punch: combination treatment in chronic myeloid leukemia
    Kendra L Sweet
    Department of Malignant Hematology, H Lee Moffitt Cancer Center and Research Institute, 13131 Magnolia Drive, 3 East, Rm 3056H, Tampa, FL 33612, United States
    Crit Rev Oncol Hematol 88:667-79. 2013
    ..This review examines the pathways, molecular targets, and potential new therapeutics that, with TKIs, may provide an effective "one-two punch" to cure CML...
  23. ncbi request reprint Role of the tumor microenvironment in mediating de novo resistance to drugs and physiological mediators of cell death
    Lori A Hazlehurst
    Clinical Investigations Program at H Lee Moffitt Cancer Center, University of South Florida, 12902 Magnolia Drive, Tampa, FL 33612, USA
    Oncogene 22:7396-402. 2003
    ..This review will focus on the bone marrow microenvironment and its role in conferring resistance to cytotoxics and physiological mediators of cell death...

Research Grants4

  1. Role of Bim in mediating CAM-DR in hematopoietic tumors
    Lori Hazlehurst; Fiscal Year: 2009
    ..In this proposal we will test whether disrupting beta 1 integrin mediated signaling increases the potency of standard chemotherapy in the bone marrow microenvironment. ..
  2. Role of Bim in mediating CAM-DR in hematopoietic tumors
    Lori A Hazlehurst; Fiscal Year: 2010
    ..In this proposal we will test whether disrupting beta 1 integrin mediated signaling increases the potency of standard chemotherapy in the bone marrow microenvironment. ..